Issue Date: June 14, 2010
FDA Struggles To Keep Up In India
When Strativa Pharmaceuticals announced in February that it could not launch a new product, the only reason, the New Jersey-based firm said in a statement, was that the U.S. Food & Drug Administration had not inspected the plant in India where the drug was to be made because of “an agency-wide restriction on foreign travel to India.”
A record obtained by C&EN of FDA’s inspections of Indian pharmaceutical facilities during . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society